EDSA News and Press, Edesa Biotech Inc. From 05/14/21

Edesa Biotech (EDSA): FQ2 GAAP EPS of -$0.19 beats by $0.10.Cash and cash equivalents of $10.97MPress Release For further details see: Edesa Biotech EPS beats by $0.10

TORONTO, ON / ACCESSWIRE / May 14, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported financial results for the three and six months ended March 31, 2021 and provided an update on its busine...

Virtual event scheduled for Thursday, April 29 at 1 pm Eastern Time TORONTO, ON / ACCESSWIRE / April 22, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that it will host a key opin...

Edesa Biotech (EDSA) shares up more than 16% premarket after the company announced that it has entered into a definitive license agreement to acquire additional global rights to a non-steroidal anti-inflammatory technology that forms the basis of the company's EB01 and EB02 drug can...

Support.com (SPRT) +271% as Greenidge Generation Holdings to go public via merger with the company.Seneca Biopharma (SNCA) +30%.Cemtrex (CETX) +21%.Marker Therapeutics (MRKR) +19%.Acer Therapeutics (ACER) +19%.Kansas City Southern (KSU) +17% as Canadian Pacific to buy the company fo...

TORONTO, ON / ACCESSWIRE / March 22, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that it has entered into a definitive license agreement under which the company, through a subsidiary...

Edesa Biotech ([[EDSA]] +7.3%) announces that it has completed enrollment of more than 50% of the patients planned for the Phase 2 portion of its ongoing Phase 2/3 clinical study evaluating the company's EB05 drug candidate as a single-dose treatment for hospitalized COVID-19 patients with or...

TORONTO, ON / ACCESSWIRE / March 15, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of more than 50% of the patients planned for the Phase 2 portion of ...

Edesa Biotech (EDSA) announces that it has completed enrollment of the first cohort of a Phase 2b clinical study evaluating the company's drug candidate EB01 as a monotherapy for chronic Allergic Contact Dermatitis ((ACD)), a potentially debilitating condition and occupational illness.Edesa r...

TORONTO, ON / ACCESSWIRE / March 9, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that it has completed enrollment of the first cohort of a Phase 2b clinical study evaluating the compa...